In contrast, Cannella and colleagues were doubtful of IGF-1 being a good therapeutic agent in MS as they showed that administration of IGF-1 at different time points during the acute and chronic phases of EAE had different outcomes and even failed to enhance CNS myelin repair in EAE [170]. This evidence concerns the gene IGF1 and myeloid sarcoma.